Hjem
Universitetet i Bergen
Broegelmanns Forskningslaboratorium

Varselmelding

There has not been added a translated version of this content. You can either try searching or go to the "area" home page to see if you can find the information there

Financial support

The core financial support for the Broegelmann Research Laboratory comes from the Broegelmann Foundation, with the fund managed by the The Broegelmann Research Board.

The Broegelmann Foundation Board 2021 (Kjøbmand J.P Broegelmanns Legat))
Left to right: Chairman, Associate at Law Bernt Jacob Pettersen, Professor Robert Bjerknes MD, PhD, Senior consultant at BRL Kate Froland (not a member of the board), Professor Lars A. Akslen MD, PhD.
Foto/ill.:
Helena Harris

Hovedinnhold

Other current major grants are listed below

  • 2019 – 2024 Piotr Mydel: National Institutes of Health (RO1 DE022597)“Bacterial peptidylarginine deiminase, a link between gums and joint disease”, Total 6.4 mill NOK
  • 2020-2023 Foundation for Research in Rheumatology (FOREUM) “Genetic variants associated with Sjögren’s syndrome leading to differential gene expression in males and females and their functional impact on the immune system”; Karolinska Institutet v/Marie Wahren Herlenius er coordinator, UiB og Harvard er partnere. Appel/Jonsson Total 1 500 000 NOK
  • 2020 – 2023 Piotr Mydel: National Science Center Poland (2019/33/B/NZ4/01889) “Protein Carbamylation in Hemostatic Dysfunctions in Chronic Kidney Disease”; Total 505 000 €
  • 2020 – 2023 Piotr Mydel: EU Joint Programme – Neurodegenerative Disease Research (EC/JPND; ES655895) “Alzheimer’s disease as a comorbidity of chronic periodontitis with Porphyromonas gingivalis as a causative link between both diseases” Total 575 000 €
  • 2021 – 2024 Piotr Mydel: EC/Grieg “Novel mechanisms of PAD activity regulation. Substrate specificity and and activation of peptidyl arginine deiminases in the context of RA” Total 499 000 €
  • 2019-2024 Roland Jonsson: The European Commission Horizon 2020 contract NECESSITY (IMI2-JU/EU/H2020 nr. 806975) “New Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifying patients”
  • 2021-2025 Yenan Bryceson: Norwegian Research Council ‘’Engineering NK cells for improved functonality in immunotherapy’’ Total 12 mill NOK
  • 2021-2025 Marie Wahren Herlenius: Norwegian Research Council ‘’The molecular basis of sex differences in Sjögren’s syndrome’’ Total 10 mill NOK

We thank the contributors for their financial support!

09.12.2022